Lisa Astor

Associate Editorial Director, Targeted Oncology, @TargetedOnc
Passionate about precision medicine in oncology.

[Targeted Oncology @TargetedOnc]

Tomorrow is our #TargetedChat with Dr. Alexander M. Lesokhin. Join us for a discussion about a multiple myeloma patient case. @LesokhinMD @sloan_kettering #MMsm

[Targeted Oncology @TargetedOnc]

How would you handle this case?

[Lisa Astor @oncolisa]

Let the #ASCO21 fun begin! Tune in to @TargetedOnc and https://t.co/8OCfOaxa9B for lots of ASCO updates throughout the weekend.

[Targeted Oncology @TargetedOnc]

Here is a look back at the FDA happenings from the month of May 2021. #FDA
https://t.co/49XliWiYCn

[Targeted Oncology @TargetedOnc]

BREAKING: The FDA granted approval to adjuvant nivolumab as treatment of completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease in patients who have received neoadjuvant chemoradiotherapy. #esocsm
https://t.co/WZyVVKympb

[Lisa Astor @oncolisa]

Ahead of the #FDA ODAC meetings Tuesday through Thursday, read up about the indications being discussed: https://t.co/Lid0uAjUZf

[Lisa Astor @oncolisa]

@pjsbyrne2012, I have passed along to our subscription team to make this change for you as soon as possible.

[Lisa Astor @oncolisa]

APPROVED! The #FDA has expanded the indications for lorlatinib for the frontline treatment of patients with ALK+ NSCLC. @ALKLungCancer #ALK #LCSM https://t.co/R7etWeN1TI

[Lisa Astor @oncolisa]

APPROVED! The #FDA has approved cemiplimab for the frontline treatment of patients with PD-L1 high advanced non-small cell lung cancer in the frontline setting. #LCSM https://t.co/IgBdMQq78T

[Lisa Astor @oncolisa]

APPROVED! The #FDA has approved trilaciclib to reduce chemotherapy-induced bone marrow suppression for extensive-stage small cell lung cancer https://t.co/ZETxCSNGNZ

[Lisa Astor @oncolisa]

APPROVED! The #FDA has approved the combination of nivolumab and cabozantinib in the frontline setting for the treatment of patients with advanced renal cell carcinoma #kcsm https://t.co/kVF1X2F3Pp

[Mark Lewis, MD, FASCO @marklewismd]

Looking forward to a discussion of IO in mCRC #crcsm #TargetedChat

[Targeted Oncology @TargetedOnc]

Mark your calendars🗓️for the next #TargetedChat tweet chat Wednesday 1/20 at 6pm EST with Dr. Lewis @marklewismd of @Intermountain on #ColonCancer!
Check out the patient case for discussion below & share your thoughts on the treatment decisions in our poll in the comments! #crcsm

[Targeted Oncology @TargetedOnc]

Mark your calendars 🗓️for our next tweet chat, where we will discuss the case of a patient with stage IV #ColorectalCancer with Dr. Lewis @marklewismd of @Intermountain. Join us Jan 20 at 6pm EST, and stay tuned for a sneak peek of the patient case before #GI21! #TargetedChat

[4baseCare @4baseCare]

Year 2020 proved to be a big year with many FDA approvals.

We hope 2021 would bring even more breakthrough personalized cancer treatment therapies.

Read this interesting article to know more;

https://t.co/E0lF4nRpVs

[Targeted Oncology @TargetedOnc]

"It’s the medical breakthrough of our lifetime," wrote Mike Hennessy Sr. of @MJHLifeSciences.
https://t.co/pxP2cujfpU #COVID19

[Lisa Astor @oncolisa]

APPROVED! The #FDA has approved margetuximab plus chemotherapy for the treatment of patients with metastatic HER2+ breast cancer https://t.co/VTaqsue5OJ

[Lisa Astor @oncolisa]

Hematology experts provide insight into the most impactful takeaways from #ASH20 @TargetedOnc https://t.co/DAgcTfPP34

[Lisa Astor @oncolisa]

.@TargetedOnc wants to know, what area do you think saw the most practice-changing data from ASH this year?

[Targeted Oncology @TargetedOnc]

ASH POLL: In what area do you think the most important data came from at the 2020 @ASH_hematology Annual Meeting?
Share in the comments what your top #ASH20 abstracts were. #Hematology

[Lisa Astor @oncolisa]

Follow @TargetedOnc and https://t.co/q3A6mY8Tch all weekend for live coverage from #ASH20!